236 related articles for article (PubMed ID: 32506298)
1. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
2. ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer.
Sato T; Saito M; Nakajima S; Saito K; Katagata M; Fukai S; Okayama H; Sakamoto W; Saze Z; Momma T; Mimura K; Kono K
Gastric Cancer; 2023 May; 26(3):379-392. PubMed ID: 36811690
[TBL] [Abstract][Full Text] [Related]
3. A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.
Huang K; Sun R; Chen J; Yang Q; Wang Y; Zhang Y; Xie K; Zhang T; Li R; Zhao Q; Zou L; Li J
Cell Cycle; 2020 Apr; 19(7):758-771. PubMed ID: 32093567
[TBL] [Abstract][Full Text] [Related]
4. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors.
Rehman H; Chandrashekar DS; Balabhadrapatruni C; Nepal S; Balasubramanya SAH; Shelton AK; Skinner KR; Ma AH; Rao T; Agarwal S; Eich ML; Robinson AD; Naik G; Manne U; Netto GJ; Miller CR; Pan CX; Sonpavde G; Varambally S; Ferguson JE
JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35852858
[TBL] [Abstract][Full Text] [Related]
5. Chromatin remodeling gene AT-rich interactive domain-containing protein 1A suppresses gastric cancer cell proliferation by targeting PIK3CA and PDK1.
Zhang Q; Yan HB; Wang J; Cui SJ; Wang XQ; Jiang YH; Feng L; Yang PY; Liu F
Oncotarget; 2016 Jul; 7(29):46127-46141. PubMed ID: 27323812
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
[TBL] [Abstract][Full Text] [Related]
7. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Samartzis EP; Gutsche K; Dedes KJ; Fink D; Stucki M; Imesch P
Oncotarget; 2014 Jul; 5(14):5295-303. PubMed ID: 24979463
[TBL] [Abstract][Full Text] [Related]
8. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer.
Gonzalez ME; DuPrie ML; Krueger H; Merajver SD; Ventura AC; Toy KA; Kleer CG
Cancer Res; 2011 Mar; 71(6):2360-70. PubMed ID: 21406404
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of EZH2 and activation of ERRγ synergistically suppresses gastric cancer by inhibiting FOXM1 signaling pathway.
Huang B; Mu P; Yu Y; Zhu W; Jiang T; Deng R; Feng G; Wen J; Zhu X; Deng Y
Gastric Cancer; 2021 Jan; 24(1):72-84. PubMed ID: 32529327
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of ARID1A and PI3K/AKT pathway alterations in cholangiocarcinoma.
Tessiri S; Techasen A; Kongpetch S; Namjan A; Loilome W; Chan-On W; Thanan R; Jusakul A
PeerJ; 2022; 10():e12750. PubMed ID: 35070505
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA PART1 restrains aggressive gastric cancer through the epigenetic silencing of PDGFB via the PLZF-mediated recruitment of EZH2.
Han H; Wang S; Meng J; Lyu G; Ding G; Hu Y; Wang L; Wu L; Yang W; Lv Y; Jia S; Zhang L; Ji J
Oncogene; 2020 Oct; 39(42):6513-6528. PubMed ID: 32901105
[TBL] [Abstract][Full Text] [Related]
12. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
13. ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation.
Kase K; Saito M; Nakajima S; Takayanagi D; Saito K; Yamada L; Ashizawa M; Nakano H; Hanayama H; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Shiraishi K; Kohno T; Kono K
Carcinogenesis; 2021 Feb; 42(1):21-30. PubMed ID: 33196828
[TBL] [Abstract][Full Text] [Related]
14. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
[TBL] [Abstract][Full Text] [Related]
15. AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells.
Lee D; Yu EJ; Ham IH; Hur H; Kim YS
Onco Targets Ther; 2017; 10():4153-4159. PubMed ID: 28860825
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of ARID1A negative expression in gastric cancer.
Ashizawa M; Saito M; Min AKT; Ujiie D; Saito K; Sato T; Kikuchi T; Okayama H; Fujita S; Endo H; Sakamoto W; Momma T; Ohki S; Goto A; Kono K
Sci Rep; 2019 May; 9(1):6769. PubMed ID: 31043675
[TBL] [Abstract][Full Text] [Related]
18. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
19. CLDN4 silencing promotes proliferation and reduces chemotherapy sensitivity of gastric cancer cells through activation of the PI3K/Akt signalling pathway.
Luo J; Wang H; Chen H; Gan G; Zheng Y
Exp Physiol; 2020 Jun; 105(6):979-988. PubMed ID: 31856376
[TBL] [Abstract][Full Text] [Related]
20. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
